Drug profile · INN
talimogene laherparepvec
IMLYGIC
talimogene laherparepvec (IMLYGIC) is a melanoma cell disrupting agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX51
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — talimogene laherparepvec
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
talimogene laherparepvec (IMLYGIC) is a melanoma cell disrupting agent.
Key facts
INN talimogene laherparepvec
Brand IMLYGIC
Mechanism Melanoma cell disrupting agent
Target Melanoma cell
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX51
Mechanism of action
Melanoma cell disrupting agent
Primary target: Melanoma cell
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is talimogene laherparepvec?
talimogene laherparepvec (IMLYGIC) is a melanoma cell disrupting agent.
What is the brand name for talimogene laherparepvec?
IMLYGIC is a marketed brand name for talimogene laherparepvec. Check FDA Drugs@FDA for the current US label holder and prescribing information.